Resveratrol Improves Cardiomyopathy in Dystrophin-deficient Mice through SIRT1 Protein-mediated Modulation of p300 Protein*§

Atsushi Kuno†‡§, Yusuke S. Hori†, Ryusuke Hosoda†, Masaya Tanno†, Tetsuji Miura‡, Kazuaki Shimamoto§, and Yoshiyuki Horio†§

From the †Department of Pharmacology and ‡Second Department of Internal Medicine, Sapporo Medical University School of Medicine and §Sapporo Medical University, Sapporo 060-8556, Japan

Background: Dystrophin deficiency leads to life-threatening cardiomyopathy, whereas cardiac p300 promotes cardiac hypertrophy/failure.

Results: The SIRT1 activator resveratrol inhibited p300 protein up-regulation and attenuated cardiomyopathy in dystrophin-deficient mice, and SIRT1-induced p300 down-regulation was mediated via its deacetylation and ubiquitination.

Conclusion: SIRT1 activation ameliorates dystrophic cardiomyopathy by targeting p300.

Significance: Negative regulation of p300 is a novel cardioprotective mechanism of SIRT1.

Cardiomyopathy is the main cause of death in Duchenne muscular dystrophy. Here, we show that oral administration of resveratrol, which leads to activation of an NAD+/H11001-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice. The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and resveratrol administration down-regulated the p300 protein level. In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α1-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated p300 protein levels but not p300 mRNA levels. In addition, activation of atrial natriuretic peptide promoter by p300 was inhibited by SIRT1. We found that SIRT1 induced p300 down-regulation via the ubiquitin-proteasome pathway by deacetylation of lysine residues for ubiquitination. These findings indicate the pathological significance of p300 up-regulation in the dystrophic heart and indicate that SIRT1 activation has therapeutic potential for dystrophic cardiomyopathy.

Cardiomyopathy is frequently found in patients with muscular dystrophies as follows: disorders caused by loss-of-function mutations in genes encoding dystrophin, sarcoglycans, or other dystroglycan complex components. Duchenne muscular dystrophy (DMD), the most common and serious type of muscular dystrophy, is caused by a mutation in the dystrophin gene. Because mechanical ventilation prevents death from respiratory failure (1), heart failure is a major cause of mortality in DMD patients. Although treatment with angiotensin-converting enzyme inhibitors and β-blockers provide benefits in patients with cardiac dysfunction associated with DMD (2), it is still progressive under these medications. Therefore, it is important to analyze the mechanism underlying dystrophic cardiomyopathy and to develop new medical approaches.

Protein lysine acetylation/deacetylation is emerging as an important regulatory mechanism of cellular functions. The transcriptional co-activator p300 acetylates histones and transcription (co-)factors and controls physiological processes such as cell proliferation, development, and survival. Although p300 is essential for cardiac development (3), it also plays a key role in cardiac hypertrophy and heart failure by acetylating and activating myocyte enhancer factor-2 (4) and GATA4 (5) transcription factors. The dose of p300 seems to be critical for development of cardiac hypertrophy, because overexpression of p300 induces cardiomyocyte hypertrophy in vitro and in vivo, whereas down-regulating p300 ameliorated cardiomyopathy (4). In addition, cardiac fibrosis impairs myocardial diastolic function in hypertrophied and failing hearts, and p300 promotes tissue fibrosis by binding to and activating Smad3 (6). Therefore, p300 is a key contributor to cardiac hypertrophy and fibrosis, but the regulatory mechanism of p300 is not fully elucidated. It is also unclear whether p300 participates in the cardiac pathology of DMD.

SIRT1 is an NAD+/H9251-dependent class III protein/histone deacetylase, which regulates numerous cellular processes such as stress response, cell survival, cell cycle, development, and metabolism by deacetylating target proteins (7). Recently,
SIRT1 was found to be an attractive therapeutic target for various diseases (7), and a polyphenol resveratrol was identified as a SIRT1 activator (8), although the mechanism of SIRT1 activation by resveratrol seems to be mediated by other molecules such as AMP-dependent protein kinase (7, 9–11). We have shown that SIRT1 is a nucleocytoplasmic shuttling protein (12, 13). Furthermore, we found that resveratrol increases superoxide dismutase 2, inhibits cardiomyocyte death, and prolongs the life span in TO-2 cardiomyopathic hamsters (14). We also recently reported that resveratrol reduces oxidative stress and ameliorates the skeletal muscle pathology in mdx mice (15). Therefore, SIRT1 activation by resveratrol may be a new potential treatment of cardiomyopathy related to dystrophin deficiency.

In this study, we report that p300 protein but not mRNA is up-regulated in the hearts of dystrophin-deficient mdx mice and that long term resveratrol administration to mdx mice suppresses cardiac p300 up-regulation and improves cardiomyopathy. We also show that the p300 protein level is reciprocally regulated by acetylation and deacetylation. Resveratrol down-regulates the p300 protein level via activation of SIRT1, which deacetylates p300 and promotes ubiquitin-dependent degradation. Our study reveals the significance of p300 regulation in dystrophic cardiomyopathy and also the therapeutic potential of SIRT1 activators in DMD.

**EXPERIMENTAL PROCEDURES**

**mdx Mice—**All in vivo experiments were conducted according to The Animal Guideline of Sapporo Medical University and approved by the Animal Use Committee of Sapporo Medical University. Male C57BL/10ScN-Dmd mdx/ mice (mdx mice) and control C57BL/10 mice were purchased from the Oriental Yeast Co. Ltd. (Tokyo, Japan). Resveratrol (food grade, ChromaDex) was mixed with a powdered diet (4 g/kg meal) and orally administered ad libitum to mice for 32 weeks beginning at 9 weeks of age, after which the mice were sacrificed and the hearts examined.

**Echocardiography—**Echocardiography was performed under anesthesia with isoflurane, using Vivid-i ultrasound (GE Healthcare) with an 11.5-MHz probe. The left ventricle was assessed in the parasternal long axis view. The interventricular septal thickness, left ventricular posterior wall thickness, left ventricular dimension, and diastolic posterior wall velocity were measured from M-mode tracings of the left ventricles obtained at the mid-papillary muscle level with a sweep speed of 50 mm/s.

**Tissue Analysis—**Frozen heart tissue was prepared for the evaluation of cardiomyocyte cross-sectional area and immunostaining as described previously (15). To quantify the fluorescence-positive area, images were captured under the same conditions. To measure the myocyte minimal Feret’s diameter as muscle fiber cross-sectional size (16), left ventricular sections were stained with FITC-conjugated wheat germ agglutinin (Sigma). Cardiomyocyte cell membrane images were captured digitally, and the minimal Feret’s diameter was analyzed using ImageJ software (National Institutes of Health). For immunostaining, tissue sections were fixed with 4% paraformaldehyde, blocked, and incubated with antibodies against fibronectin and acetyl histone H3K9/K14. The percentage of the fibronectin-stained area was analyzed by using ImageJ software from eight independent images of sections of the left ventricle from 4 to 5 mice in each group. Immunoblot and quantitative RT-PCRs were performed as described in the supplemental material.

**Constructs and Transfection—**The expression constructs for wild-type SIRT1-EGFP and dominant-negative mutant (H355Y) SIRT1-EGFP were described previously (12). FLAG-p300 and p300-HA expression constructs were kindly provided by Dr. Richard Eckner (University of Zurich, Zurich, Switzerland) and Dr. Masaki Ikeda (Tokyo Medical and Dental University, Tokyo, Japan). To generate the blank control vector of p300-HA (CMV/Δp300), the p300-HA plasmid was digested with NotI and HindIII. The vector overhangs were then blunted by using T4 DNA polymerase (New England Biolabs), and the blunt ends were ligated with the DNA ligation kit Mighty Mix (Takara-Bio). The FLAG-PCAF (p300/CBP-associated factor) expression vector was kindly provided by Dr. Yoshihiro Nakatani (Dana Farber Cancer Institute, Boston). The GATA4-FLAG expression vector was kindly provided by Dr. Mona Nemer (University of Ottawa, Ottawa, Canada). The atrial natriuretic peptide (ANP)-luciferase reporter was constructed by subcloning PCR-amplified inserts corresponding to the promoter sequence of Nppa from mouse genomic DNA (~517 to +30) into the KpnI and XhoI sites of the pGL3 basic luciferase expression vector (Promega), using the following primers: 5′-GGTACCGATGAATCTAGGTTGGAAGCTA-3′ and 5′-CTCGAGCTCTCTCTCTCTCTCTCAGCTTTTTGCTC-3′. Lipopectamine LTx with Plus Reagent (Invitrogen) was used to transfect plasmids into neonatal rat cardiomyocytes, COS7, and HEK293 cells. A QuickChange XL mutagenesis kit (Stratagene) was used for site-directed mutagenesis. The following primer sets were used for mutagenesis: p300-K1020R/K1024R_sense 5′-GAGAAGACACTGAGTTAGAAC-TGAAATAGAGAGGAGGAGGACC-3′ and K1020R/K1024R_antisense, 5′-GGTTTCTCTCTCTCTATTTCTAGCTTCTTTC-3′.

**Luciferase Assay—**Plasmid DNA (0.6 μg/well) was transfected with PRL-CMV (1 ng/well) into HEK293 cells on a 24-well dish using Lipopectamine LTx with Plus Reagent (Invitrogen). The amount of DNA transfected to a well was equalized by the addition of the control EGFP-N3 plasmid. Luciferase activity was assessed by normalization of transfection efficiency with Renilla luciferase with the Dual-Luciferase reporter assay system kit (Promega). Results were obtained from at least three independent experiments.

**Analysis of p300 Acetylation and Ubiquitination—**After FLAG-p300 transfection and experimental treatments, COS7 cells were harvested, and whole-cell extracts were prepared using lysis buffer (CellLytic M (Sigma)) with protease inhibitor mixture (Nacalai Tesque)). The cell lysates were incubated with 2 μg of an anti-FLAG antibody or normal IgG at 4 °C overnight. To analyze p300 acetylation status in cardiac tissues, tissues were homogenized and lysed in lysis buffer (CellLytic MT (Sigma)) containing protease inhibitor mixture, trichostatin A (1 μM), and nicotinamide (10 mM). Heart lysates (1500 μg) were incubated with 4 μg of normal mouse IgG or mouse anti-p300 antibody at 4 °C overnight. The immunoprecipitates were bound to Protein A/G PLUS-agarose (Santa Cruz Biotechnol-
Ubiquitin-Proteasome-dependent Degradation of p300 by SIRT1

RESULTS

Resveratrol Prevents Cardiomyopathy and Restores Cardiac Function in Dystrophin-deficient mdx Mice—At the age of 41 weeks, both the heart weight and heart weight-to-body weight ratio were higher in the untreated mdx mice than in control C57BL/10 mice (Fig. 1A); these changes were completely suppressed in the resveratrol-treated mdx mice (Fig. 1A). The elevation of ANP mRNA, a marker of cardiac hypertrophy, in the mdx heart was also suppressed by resveratrol treatment (Fig. 1B). The minimal Feret’s diameter of the cardiomyocyte in the left ventricle was significantly larger in the untreated mdx mice than in control mice, and resveratrol treatment significantly suppressed this increase (Fig. 1C). Echocardiography at 40 weeks old showed that the interventricular septal thickness at end diastole and left ventricular posterior wall thickness at end diastole in mdx mice was thicker than in control mice (Fig. 1D and supplemental Table S1). The interventricular septal thickness at end diastole in resveratrol-treated mdx mice was comparable with that in controls. Although the systolic function, measured by fractional shortening and ejection fraction, was comparable among the three groups (supplemental Table S1), the diastolic posterior wall velocity, an index of diastolic function, was significantly slower in the untreated mdx hearts than in control hearts (Fig. 1, D and E). The diastolic posterior wall velocity was restored in the resveratrol-treated mdx mice (Fig. 1, D and E).

Immunostaining showed the increased percentage of the fibronecstin-stained area of the left ventricle, especially at the interstitial space, in the control mdx mice, and resveratrol treatment significantly suppressed this increase (Fig. 1F). The cardiac mRNA levels of the collagen genes Col1a1, Col1a2, and Col3a1, which mark fibrosis, were significantly up-regulated in untreated mdx mice compared with control mice, whereas cardiac collagen gene expression did not differ significantly between control C57BL/10 and resveratrol-treated mdx mice (Fig. 1G). In addition, the increase in mRNA of a myofibroblast marker α-smooth muscle actin in the mdx heart was significantly suppressed by resveratrol treatment (Fig. 1G).

Histone H3 acetylation at Lys-9 and Lys-14 (H3K9/K14) was elevated in the mdx hearts, suggesting that protein acetylation might be increased in mdx mice (Fig. 1H). Resveratrol administration decreased the acetyl-H3K9/K14 level in the mdx heart (Fig. 1H), indicating that resveratrol increased histone deacetylase activity and/or inhibited histone acetyltransferase activity. We next examined the histone acetyltransferase p300. Immunoblotting showed that the myocardial p300 protein level was up-regulated 2.8-fold in mdx mice compared with control mice, and this increase was completely suppressed by resveratrol treatment (Fig. 1I). In contrast, the myocardial p300 mRNA levels were comparable in the mdx and control mice (Fig. 1J). The SIRT1 protein and mRNA levels in the heart were unchanged in the mdx mice (Fig. 1I and supplemental Fig. S1A). Down-regulation of sarco(endo)plasmic reticulum calcium ATPase 2a (Serca2a) is a hallmark of failing hearts and contributes to abnormal cardiac function (17). We found that Serca2a mRNA level was significantly lower in the untreated mdx heart than the control heart, which was ameliorated by resveratrol administration (supplemental Fig. S1B). Resveratrol did not suppress the up-regulation of the NADPH oxidase subunits Nox2 and Nox4, mediators of cardiac hypertrophy and fibrosis (supplemental Fig. S1C). Phosphorylation of extracellular signal-regulated kinases (ERK) 1/2, other mediators of cardiac hypertrophy, was not suppressed by resveratrol in the mdx heart (supplemental Fig. S2, A and B). Although AMP-dependent protein kinase is reported to be a target of resveratrol (18), phosphorylation of AMP-dependent protein kinase α and its downstream target acetyl-CoA carboxylase was not modulated by resveratrol (supplemental Fig. S2, C and D).

Resveratrol Suppresses the Up-regulation of p300 Protein—To confirm the significance of p300 protein up-regulation in cardiac hypertrophy, we employed cultured neonatal rat cardiomyocytes. As reported previously (5), an α1-agonist phenylephrine significantly increased the p300 protein level (Fig. 2A) and cell surface area (Fig. 2B) in isolated cardiomyocytes. Phenylephrine also increased the level of α-tubulin, another marker of cardiac hypertrophy (Fig. 2, A and D). Knockdown of p300 by siRNA canceled the phenylephrine-induced increases in both α-tubulin level and cardiomyocyte surface area (Fig. 2, A and B). Furthermore, the ANP promoter activity was increased according to the p300 level, indicating that the p300 level regulates ANP expression (Fig. 2C). The vector control (CMV/β (Δp300)) did not affect ANP promoter activity (supplemental Fig. S3A). Similar to p300-siRNA, resveratrol significantly inhibited up-regulation of p300, α-tubulin, and ANP expression and also cellular hypertrophy induced by phenylephrine (Fig. 2, D, F, and G). Interestingly, phenylephrine did not change the p300 mRNA level (Fig. 2E). Chromatin immunoprecipitation experiments showed that phenylephrine increased p300 binding to the ANP promoter region at −197 to +14 (Fig. 2H), which contains the binding site of GATA4 (19), one of the partners of p300. Phenylephrine increased global acetyl-H3K9/K14 level (supplemental Fig. S3B) and also acetyl-H3K9 level at the ANP promoter (supplemental Fig. S3C). Resveratrol inhibited the increase of global acetyl-H3K9/K14 levels by phenylephrine (supplemental Fig. S3B). The levels of p300 and acetyl H3K9 at the ANP promoter region were also reduced by resveratrol treatment (Fig. 2H and supplemental Fig. S3C). These results indicate that phenylephrine up-regulated the p300 protein level, which induced the cardiomyocyte hypertrophic response, and suggest that resveratrol inhibited cardiomyocyte hypertrophy via inhibition of p300 protein up-regulation.

Resveratrol Down-regulates p300 through SIRT1—We next examined how resveratrol down-regulates the p300 protein level. Resveratrol decreased the p300 protein level in neonatal rat cardiomyocytes and C2C12 myoblast cells (Fig. 3, A and B); however, resveratrol did not reduce the p300 mRNA level (Fig. 3C). We next examined whether SIRT1 is involved in resveratrol’s function. SIRT1 was knocked down by siRNA in C2C12 (Fig. 3D), and SIRT1-siRNA abolished resveratrol’s down-regulation of p300 in C2C12 cells, showing that SIRT1 is involved

ogy) and then analyzed by anti-acetylated lysine (Cell Signaling) or anti-ubiquitin antibody (Santa Cruz Biotechnology).

Statistics—Data are expressed as means ± S.E. Comparisons between multiple groups were made using one-way analysis of variance followed by a post hoc Student-Neuman-Keuls test. The difference was considered significant if the p was < 0.05.
Ubiquitin-Proteasome-dependent Degradation of p300 by SIRT1

in this process (Fig. 3D). SIRT1 knockdown (supplemental Fig. S4) also canceled the anti-hypertrophic effect of resveratrol in cardiomyocytes (Fig. 3E). However, in COS7 cells, inhibiting SIRT1 activity by nicotinamide increased the level of FLAG-tagged p300 protein (Fig. 3F). To examine whether SIRT1 suppresses the cardiac p300 level in vivo, we crossed SIRT1 conditional mutant mice (SIRT1<sup>floxed/floxed</sup>) with transgenic mice carrying a cre transgene with a mutated estrogen receptor
ligand-binding domain under the α-myosin heavy chain promoter. Western blots of heart homogenates from cardiomyocyte-specific SIRT1 conditional knock-out mice (SIRT1HKO) showed a band of mutant SIRT1s with a lower molecular weight than that of wild-type SIRT1 (Fig. 3G). Cardiac p300 protein level was elevated in the SIRT1HKO compared with the SIRT1fl/fl (Fig. 3G). These data indicate that SIRT1 activation by resveratrol decreases p300 protein via its deacetylation activity.

We further examined whether SIRT1 down-regulates p300 protein via its deacetylation activity. In COS7 cells, the level of p300-FLAG protein was reduced by co-expressing wild-type SIRT1 (SIRT1-WT) but not a deacetylase-inactive mutant SIRT1 (SIRT1-HY) (Fig. 4A). The increased ANP promoter activity by p300 overexpression was suppressed by co-expressing SIRT1-WT (Fig. 4B). SIRT1-HY failed to suppress ANP’s transactivation by p300, indicating that SIRT1 inhibited the ANP promoter activity via its deacetylation activity (Fig. 4C). Alone, neither SIRT1-WT nor SIRT1-HY affected the ANP promoter activity (Fig. 4, B and C). Phenylephrine-induced cardiomyocyte hypertrophy was also completely inhibited by the overexpression of SIRT1-WT but not by SIRT1-HY (Fig. 4, D and E).

Down-regulation of p300 Is Associated with Its Deacetylation by SIRT1—Lys-1020 and Lys-1024 on p300 are reported to be targets for both sumoylation and deacetylation induced by SIRT1 activation (20). We therefore examined whether deacetylation of p300 by SIRT1 is associated with its down-regulation. Immunoprecipitation experiments showed that the acetylated p300 level was increased by nicotinamide (Fig. 5A) or the specific SIRT1 inhibitor EX527 (Fig. 5B). Trichostatin A, which inhibits class I and II histone deacetylases, also increased the acetylated p300 level but less potently than nicotinamide (Fig. 5A). SIRT1-WT but not SIRT1-HY greatly decreased the levels of acetylated p300 and total p300 (Fig. 5C). We also tested whether p300 acetylation might conversely up-regulate the p300 protein. Because p300 is acetylated by p300 itself (21), we co-expressed FLAG-tagged p300 and HA-tagged p300. HA-tagged p300 co-expression increased the expression level of FLAG-tagged p300 and vice versa (Fig. 5D). The p300 protein level was also markedly increased when co-expressed with...
PCAF that acetylates p300 and augments its activity (Fig. 5, E and F) (22). This increase was cancelled by co-expressing SIRT1 (Fig. 5 F). However, anacardic acid, which inhibits protein acetylase activity of p300 and PCAF, reduced the p300 protein level in a dose-dependent manner (Fig. 5 G). Anacardic acid also suppressed the up-regulation of p300 protein induced by phenylephrine in neonatal rat cardiomyocytes (Fig. 5 G). To investigate whether p300 acetylation is associated with up-regulation of p300 protein in vivo, we analyzed hearts from cardiomyocyte-specific SIRT1 knock-out mice. Acetylated p300 was increased in the heart of SIRT1 knock-out mice, where p300 protein level was up-regulated (Fig. 5 H). These data suggest that p300 acetylation status regulates the p300 protein level.

**SIRT1 Down-regulates p300 through the Ubiquitin-Proteasome Pathway**—Although p300 ubiquitination has been reported (23, 24), the relationship between p300 ubiquitination and acetylation has not been examined. We hypothesized that deacetylation of p300 by SIRT1 might induce degradation of p300 via the ubiquitin-proteasome pathway. A proteasome inhibitor MG132 blocked down-regulation of p300 by SIRT1 overexpression (Fig. 6A) and by resveratrol (Fig. 6B). MG132 did not affect deacetylation of p300 by SIRT1 (Fig. 6C). In the presence of MG132, SIRT1 overexpression promoted ubiquitination of p300 as well as p300 deacetylation (Fig. 6D). These findings suggest that SIRT1 deacetylates p300 and promotes ubiquitination and degradation of p300.

Deacetylation of p300 at Lys-1020 and Lys-1024 by SIRT1 facilitates p300 sumoylation in these lysine residues (20). These are in a potential ubiquitination region (amino acid residues 964–1194) (Fig. 6E) (23). Therefore, we tested whether p300 Lys-1020 and Lys-1024 are ubiquitination targets. Overexpressing SIRT1 did not reduce the level of a mutant FLAG-p300 in which the two lysine residues were replaced with arginine (p300-KR) (Fig. 6F). In the presence of MG132, the ubiquitination level of the mutant p300 was not because of a lower affinity for SIRT1.
DISCUSSION

Our results provide the first evidence of the effectiveness of long term resveratrol treatment for cardiomyopathy in dystrophin-deficient mice. We found elevated p300 protein levels in mdx heart tissues. High p300 levels are found in the failing heart in humans and mice (4), and combination studies using cardiac p300 transgenic mice and p300 heterozygous knock-out mice showed that mortality and cardiac mass are directly regulated by myocardial p300 protein levels (4). Because a 1.5–3.7-fold overexpression of p300 causes prominent cardiac hypertrophy in p300-transgenic mice (4), the 2.8-fold increase in p300 protein level in the mdx heart is sufficient to induce cardiac hypertrophy. Resveratrol inhibited cardiac p300’s up-regulation and hypertrophy in mdx mice (Fig. 1, A, C, and I), further indicating that down-regulation of p300 is responsible for the anti-hypertrophic function of resveratrol. This negative regulation of p300 is a novel mechanism for cardioprotection by resveratrol.
Resveratrol suppressed cardiac fibrosis (Fig. 1, F and G) in mdx mice. Previously, we showed that resveratrol represses skeletal muscle fibrosis in mdx mice (15) and cardiac fibrosis in cardiomyopathic TO2 hamsters (14). Down-regulation of H9251-smooth muscle actin expression in mdx hearts treated with resveratrol (Fig. 1 G) suggests that inhibiting myofibroblast differentiation from fibroblasts contributes to the anti-fibrotic action of resveratrol. Smad transcription factors, key mediators of myofibroblast transformation and tissue fibrosis, form an active transcription complex with p300 (6). Thus, the findings suggest that p300 down-regulation by resveratrol also underlies inhibition of myofibroblast formation and fibrosis in the mdx heart. Resveratrol may act in fibroblasts in addition to cardiomyocytes.

Resveratrol preserved cardiac diastolic function in mdx mice (Fig. 1 E). This seems to be attributed to inhibition of cardiac hypertrophy and fibrosis. In addition, to an extent, the maintenance of the cardiac Serca2a level (supplemental Fig. S1A) may also contribute to the improvement in cardiac function in resveratrol-treated mdx mice, because restoring cardiac Serca2a expression has a therapeutic impact in heart failure models (17), including the mdx heart (25). Overall, these findings indicate that resveratrol provides benefits that suppress or slow the development of heart failure in the dystrophin-deficient heart.

This is the first study demonstrating the relationship between p300 deacetylation and ubiquitination. In some proteins, acetylation of lysine residues is known to interfere with ubiquitin-dependent proteasomal degradation, whereas deacetylation of the protein by SIRT1 promotes its ubiquitination and degradation (26, 27). Our data strongly indicate that deacetylated lysine residues of p300 become the targets of ubiquitination, which leads to proteasomal degradation of p300. Furthermore, although SIRT1 and p300 reciprocally regulate cellular function by protein deacetylation and acetylation, respectively (26–28), this negative regulation of p300 by SIRT1 might enhance protein deacetylation induced by SIRT1.

It remains unclear how p300 protein up-regulates in the mdx heart. Our study strongly suggests that p300 acetylation is involved in the p300 up-regulation, although the p300 acetylation level in mdx hearts is unknown. Because cardiac SIRT1
Ubiquitin-Proteasome-dependent Degradation of p300 by SIRT1

expression level was not changed in mdx mice (Fig. 1I and supplemental Fig. S1A), the deacetylation rate of p300 by SIRT1 in mdx hearts might be comparable with that of control hearts. A previous study showed that pressure overload in the heart by transverse aortic constriction induced persistent p300 protein up-regulation in the heart, whereas the p300 mRNA was just transiently increased after transverse aortic constriction (4). Because autoacetylation activates p300 (21) and our data showed a mutual relationship between p300 acetylation and the p300 protein level, the transient increase in p300 activity or mRNA, induced by ERK1/2 (29) or other hypertrophic signals, may promote p300 autoacetylation, leading to p300 protein stabilization in the mdx hearts. Further study is necessary to investigate the mechanism of p300 up-regulation in mdx hearts.

These encouraging results show that resveratrol has the potential for translation into clinical situations. Evidence for the safety, pharmacokinetics, and clinical feasibility of resveratrol on obesity and metabolic disorders (30) is growing. Additionally, resveratrol has dual benefits in both cardiac and skeletal muscle (15) in mdx mice. At present, it is unknown whether resveratrol slows or reverses the progression of cardiac dysfunction administered even after the onset of cardiomyopathy in the dystrophin-deficient heart. Additional studies are needed to further establish the effectiveness of SIRT1 activation in dystrophinopathy.

REFERENCES

**JOURNAL OF BIOCHEMICAL PHYSIOLOGY**

**VOLUME 288 • NUMBER 8 • FEBRUARY 22, 2013**

**5972**